GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Alector Inc.
Alector is a biotech company specializing in immuno-neurology for the treatment of neurodegenerative diseases. Its stock price is driven by news of clinical trials. The price chart is a bet on a breakthrough in the treatment of complex diseases like Alzheimer's.
Share prices of companies in the market segment - Neuro
Alector (ALEC) is a clinical-stage biopharmaceutical company focused on using immunology to develop new treatments for neurodegenerative diseases such as Alzheimer's. We classify it as a Neuroscience company. The chart below illustrates the dynamics of this complex and risky biotech sector.
Broad Market Index - GURU.Markets
Alector is a biopharmaceutical company developing immuno-neurological drugs for the treatment of neurodegenerative diseases such as Alzheimer's. As a component of the GURU.Markets index, it represents the cutting edge of medicine. The chart below represents the entire market. See how this innovator compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
ALEC - Daily change in the company's share price Alector Inc.
Shares of Alector, a biopharmaceutical company specializing in neurodegenerative diseases, are extremely volatile. Change_co measures the market's reaction to clinical trial data. This metric is an essential component in building valuation models for cutting-edge companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Neuro
Alector, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with ALEC, which focuses on neurodegenerative diseases, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Alector is a biopharmaceutical company specializing in drugs for the treatment of neurodegenerative diseases. Neuroscience is a risky field of research. The chart below illustrates the high volatility typical of the biotech sector, reflecting the stakes associated with Alector's developments.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Alector Inc.
Alector, Inc.'s year-over-year performance is a story of developing immuno-neurological drugs for the treatment of Alzheimer's and Parkinson's diseases. Its 12-month market capitalization is entirely dependent on clinical trial data. Partnerships with giants like AbbVie and GSK are key confirmation of the potential of its unique scientific approach.
Annual dynamics of market capitalization of the market segment - Neuro
Alector, Inc. is a clinical-stage biotech focused on developing immuno-neurological drugs for the treatment of dementia. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential and high risks of this complex field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Alector is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials for neurodegenerative diseases. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Alector Inc.
Alector, a biopharmaceutical company, has a speculative market cap. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its immuno-neurological drugs for the treatment of Alzheimer's disease, the success of which determines its future.
Monthly dynamics of market capitalization of the market segment - Neuro
Developing drugs for neurodegenerative diseases is one of the riskiest and most capital-intensive areas of biotech. The chart below illustrates the volatility of a sector where company valuations depend on clinical trial data. In this environment, innovators like Alector are pursuing therapies for Alzheimer's and Parkinson's diseases.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Alector, a biopharmaceutical company focused on neurodegenerative diseases, operates by the laws of science. Its stock price is driven by research results, not market cycles. Its performance is completely disconnected from general economic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Alector Inc.
Alector, a biotech company developing immunotherapies for the treatment of neurodegenerative diseases such as Alzheimer's, is at the forefront of science. Its weekly stock price is almost entirely dependent on clinical trial results, creating extreme volatility.
Weekly dynamics of market capitalization of the market segment - Neuro
Neuroscience-focused biotech companies like Alector often move together, driven by shared news about breakthroughs or setbacks in brain disease treatments. The chart below illustrates this general sentiment within the niche. It allows one to assess the market's confidence in Alector's drugs compared to those of its competitors.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Alector is a biotech company developing immunotherapy for neurodegenerative diseases such as Alzheimer's. The chart shows that its shares are caught in a world of hope and disappointment in clinical trials, completely ignoring overall market trends.
Market capitalization of the company, segment and market as a whole
ALEC - Market capitalization of the company Alector Inc.
Alector's market capitalization reflects investors' bets on its immuno-neurological approach to treating degenerative brain diseases. The chart demonstrates the market's belief that harnessing the immune system can combat diseases like Alzheimer's. Its value reflects the potential of its cutting-edge scientific platform and partnerships with major pharmaceutical companies.
ALEC - Share of the company's market capitalization Alector Inc. within the market segment - Neuro
Alector is a biopharmaceutical company at the forefront of immunoneurology, developing treatments for neurodegenerative diseases such as Alzheimer's. Its market capitalization in the neurosciences segment reflects the enormous potential of its approach. The company's weight reflects its potential to achieve a breakthrough in one of the most complex areas of medicine.
Market capitalization of the market segment - Neuro
Here's a chart reflecting the combined weight of the entire neurological pharmaceutical sector. For Alector, at the forefront of immunoneurology, this line represents a map of hope in the fight against Alzheimer's disease. The rising chart represents an influx of capital into the industry, enabling expensive research that could lead to a major medical breakthrough.
Market capitalization of all companies included in a broad market index - GURU.Markets
Alector is a biopharmaceutical company focused on immunoneurology for the treatment of degenerative brain diseases. Its market capitalization is a bet on a breakthrough in the fight against Alzheimer's and other diseases. In the overall market, it represents a fraction of the hope for saving the mind.
Book value capitalization of the company, segment and market as a whole
ALEC - Book value capitalization of the company Alector Inc.
Alector is a biotech company focused on treating neurodegenerative diseases using immunology. Its book value is its financial resources for research, consisting of funds allocated for clinical trials. How has this research capital changed? The chart below shows.
ALEC - Share of the company's book capitalization Alector Inc. within the market segment - Neuro
Alector, Inc. is a biotech company focused on neurodegenerative diseases. Its cutting-edge science requires a substantial infrastructure: in-house R&D centers and laboratories focused on immunoneurology. The chart shows the company's share of the physical infrastructure needed to develop brain drugs.
Market segment balance sheet capitalization - Neuro
Alector, a biopharmaceutical company focused on neurodegenerative diseases, has a capital-intensive R&D business. This requires the ownership of cutting-edge laboratories. The BCap_Seg chart for the biotech sector shows that breakthrough research requires a robust scientific infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Alector's balance sheet isn't its factories, but a cutting-edge scientific platform in immunoneurology for developing drugs for Alzheimer's and Parkinson's diseases. The company's assets are its intellectual capital and research data. The chart shows how this science-intensive R&D asset compares to big pharma.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Alector Inc.
Alector's balance sheet is its R&D capital. Its entire market value is a premium for its innovative approach to treating neurodegenerative diseases through the immune system. Its schedule is a bet that its science will lead to a breakthrough in the treatment of Alzheimer's disease.
Market to book capitalization ratio in a market segment - Neuro
Alector is a biotech company developing immunotherapies for neurodegenerative diseases. Its high valuation on this chart reflects a bet on a breakthrough in one of the most challenging areas of medicine, Alzheimer's disease, where failures are very common.
Market to book capitalization ratio for the market as a whole
Alector is a biotech company focused on immuno-neurology for the treatment of degenerative brain diseases. Its market value is based on the potential of its innovative approach. This chart shows how highly the market values its chances of developing breakthrough drugs for diseases like Alzheimer's.
Debts of the company, segment and market as a whole
ALEC - Company debts Alector Inc.
Alector, a biotech company focused on immuno-neurology, uses capital to fund its cutting-edge research into treating neurodegenerative diseases. This chart shows how the company is raising significant funds to test its scientific hypotheses through expensive and lengthy clinical trials.
Market segment debts - Neuro
Alector is a clinical-stage biotech company focused on immunoneurology for the treatment of neurodegenerative diseases. Drug development in this complex field requires significant investment. This chart shows that the company is financed through equity and strategic partnerships, avoiding the burden of debt.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Alector Inc.
Alector is a biotech company focused on immunoneurology. Drug development in this complex field requires significant investment. This chart illustrates the company's reliance on external funding. It reflects the high financial risk and the significant stake it places on a scientific breakthrough that could lead to the development of fundamentally new treatments.
Market segment debt to market segment book capitalization - Neuro
Alector is a biotech company developing immunotherapies for the treatment of neurodegenerative diseases such as Alzheimer's. This is one of the most complex and risky areas in medicine. The chart shows how aggressively the sector uses debt to fund such breakthrough, yet costly, research.
Debt to book value of all companies in the market
Alector, Inc., a biopharmaceutical company focused on neurodegenerative diseases, conducts expensive and long-term clinical trials. This chart shows the overall market leverage. It allows one to assess how the company's financial strategy for raising capital for R&D is consistent with the high risks and time horizons of the immunoneurology field.
P/E of the company, segment and market as a whole
P/E - Alector Inc.
Alector is a biotech company developing immuno-neurological treatments for neurodegenerative diseases such as Alzheimer's. This chart shows how the market is pricing its innovative approach. This pricing is based on clinical trial results and the potential of its drugs to reverse the course of these devastating diseases.
P/E of the market segment - Neuro
Alector develops immuno-neurological drugs. This chart shows the average valuation for the biotech sector. It emphasizes that Alector is valued not by profits, but by the potential of its revolutionary approach to treating Alzheimer's disease, which the market may value at a significant premium.
P/E of the market as a whole
Alector, Inc. is a biopharmaceutical company using immunology to develop new treatments for neurodegenerative diseases such as Alzheimer's. This chart reflects the overall risk appetite of investors in biotech. It helps us understand whether ALEC's high valuation is based on faith in its innovative approach or is driven by overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Alector Inc.
Alector is a biotech company focused on immunoneurology for the treatment of neurodegenerative diseases such as Alzheimer's. This chart reflects the market's high, yet risky, expectations for its innovative approach. It's a bet on a scientific breakthrough in one of the most complex areas of medicine.
%20P%2FE%20Alector%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Alector-Inc.&v=1772513549241 "Chart of the company's future (projected) P/E Alector Inc.")
Future (projected) P/E of the market segment - Neuro
Alector is a biotech pioneer in the field of immunoneurology, developing drugs to treat neurodegenerative diseases like Alzheimer's by targeting the brain's immune system. The data here reflects the analysts' collective bet on the success of its revolutionary approach in this highly complex field.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772513549264 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Alector is a biotech company working at the intersection of immunology and neurodegenerative diseases like Alzheimer's. This sentiment chart shows how willing investors are to fund research in one of the most complex and risky areas of medicine, where a potential breakthrough would have enormous impact.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513549268 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Alector Inc.
Alector is a biotech company focused on harnessing the immune system to combat neurodegenerative diseases like Alzheimer's. This chart shows the financial impact of breakthrough research. It reflects investments in clinical trials that could lead to the development of a first-in-class drug.
Profit of companies in the market segment - Neuro
Alector is a clinical-stage biopharmaceutical company specializing in immunoneurology, a novel approach to treating neurodegenerative diseases such as Alzheimer's. Its future profitability depends on success in this highly complex yet socially significant field, reflecting its cutting-edge scientific advances.
Overall market profit
Alector is a biotech company focused on immunoneurology for the treatment of degenerative brain diseases. Its value depends on breakthroughs in clinical trials. There is no direct link to economics. However, the market conditions, which are influenced by this graph, determine how easily the company can raise hundreds of millions of dollars for its cutting-edge research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Alector Inc.
Alector is a biotech company specializing in immunoneurology, a new approach to treating neurodegenerative diseases such as Alzheimer's. This chart shows analysts' speculative expectations. The forecast depends entirely on the results of clinical trials of their innovative drugs.
%20profit%20of%20the%20company%20Alector%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Alector-Inc.&v=1772513549368 "Graph of future (projected) profit of the company Alector Inc.")
Future (predicted) profit of companies in the market segment - Neuro
Alector is a biotech company working at the intersection of immunology and neuroscience, developing drugs to treat neurodegenerative diseases such as Alzheimer's. The profitability forecasts for this sector, shown in the graph, show tremendous promise for breakthroughs. This chart helps assess the potential success of Alector's innovative approach.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772513549395 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Alector is a biotech company focused on immuno-neurology for the treatment of neurodegenerative diseases such as Alzheimer's. Its valuation is based on the potential of its scientific developments. Financing such long-term and risky projects is facilitated by the market optimism that accompanies the positive outlook on this chart.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513549410 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Alector Inc.
Alector is a biopharmaceutical company specializing in immunoneurology for the treatment of neurodegenerative diseases such as Alzheimer's. It has no commercial revenue. This chart shows how investors view its breakthrough scientific approach, betting that it can find the key to treating these devastating diseases.
P/S market segment - Neuro
Alector is a biopharmaceutical company focused on using immunology to develop new treatments for neurodegenerative diseases such as Alzheimer's. This chart shows the average revenue estimate for the biotech sector, helping to understand the market premium placed on innovative approaches to one of the most complex areas of medicine.
P/S of the market as a whole
Alector is a biopharmaceutical company specializing in immunoneurology—a novel approach to treating neurodegenerative diseases like Alzheimer's by activating the brain's immune system. This chart shows how the market values companies based on current revenues, providing a backdrop for analyzing companies with cutting-edge scientific concepts.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Alector Inc.
Alector is a biotech company focused on immunoneurology for the treatment of neurodegenerative diseases such as Alzheimer's. This chart reflects investors' high valuation of its potential future revenue. This valuation is a bet on the success of its innovative approach and clinical programs.
%20P%2FS%20Alector%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Alector-Inc.&v=1772513549709 "The graph of the company's future (projected) P/S Alector Inc.")
Future (projected) P/S of the market segment - Neuro
Alector is a biopharmaceutical company focused on immuno-neurology for the treatment of neurodegenerative diseases such as Alzheimer's. This chart compares market expectations for its future revenue with other neuroscience companies. The valuation reflects investors' high expectations for its innovative approach to treating brain diseases.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772513549720 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Alector is a biotech company specializing in immunoneurology for the treatment of neurodegenerative diseases such as Alzheimer's. Its value is based on the potential of its scientific developments. This graph of general market expectations is irrelevant for Alector, as its success is determined by breakthroughs in one of the most complex areas of medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513549725 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Alector Inc.
This chart shows the revenue of Alector, a biotech company focused on developing immuno-neurological drugs for the treatment of neurodegenerative diseases such as Alzheimer's. Being in the clinical stage, the company has no commercial revenue, and any revenue reflected here is the result of major partnerships.
Sales of companies in the market segment - Neuro
Alector is a clinical-stage biopharmaceutical company pioneering immunoneurology, a novel approach to treating neurodegenerative diseases such as Alzheimer's. This chart shows revenue in the neuroscience sector. It reflects the enormous need for breakthrough dementia treatments, where Alector's innovative approach has the potential to change the paradigm.
Overall market sales
Alector is a biotech company focused on immuno-neurology for the treatment of neurodegenerative diseases such as Alzheimer's. Demand for its potential drugs is enormous and independent of economic cycles. However, overall economic growth, reflected in this chart, provides long-term funding for breakthrough medical research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Alector Inc.
Alector is a clinical-stage biotech pioneering the field of immunoneurology, a novel approach to treating neurodegenerative diseases. This projected revenue chart reflects high expectations for its research. The growth is driven by expectations for the success of its clinical trials for drugs to treat Alzheimer's disease and other disorders.
%20sales%20of%20the%20company%20Alector%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Alector-Inc.&v=1772513550018 "Schedule of future (projected) sales of the company Alector Inc.")
Future (projected) sales of companies in the market segment - Neuro
Alector is a clinical-stage biotech company applying immunology to develop new treatments for neurodegenerative diseases such as Alzheimer's and dementia. This chart shows projected revenue for the entire neuroscience sector, reflecting the enormous expectations surrounding the discovery of effective drugs to treat these conditions.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772513550085 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Alector is a biotech company focused on immunoneurology for the treatment of neurodegenerative diseases. Its success is entirely dependent on scientific breakthroughs. The overall economic environment and market sentiment influence its ability to attract capital and enter into partnerships to fund cutting-edge and risky research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513550113 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Alector Inc.
Alector is a biotech company using immunology to combat neurodegenerative diseases like Alzheimer's. It is at the forefront of scientific advancement. This chart illustrates the cost of this mission, showing the R&D investment required to test innovative hypotheses in long-term clinical trials.
Market segment marginality - Neuro
Alector is a biopharmaceutical company specializing in immunoneurology, a novel approach to treating neurodegenerative diseases such as Alzheimer's. This chart reflects its financial performance. For a company at the forefront of science, outperforming competitors in profitability may be due to receiving large upfront payments from pharma giants.
Market marginality as a whole
Alector is a biotech company specializing in immunoneurology for the treatment of neurodegenerative diseases such as Alzheimer's. Its success is determined not by the economic cycles shown in this chart, but by scientific breakthroughs. The potential for developing a cure for such devastating diseases is enormous and is not dependent on market conditions.
Employees in the company, segment and market as a whole
Number of employees in the company Alector Inc.
Alector is a biotech company specializing in immunoneurology for the treatment of neurodegenerative diseases. This chart shows its growing team of scientists. The increase is directly related to progress in its clinical programs and major partnerships with pharmaceutical giants for co-development of drugs.
Share of the company's employees Alector Inc. within the market segment - Neuro
Alector is a biotech company working at the intersection of immunology and neuroscience to treat neurodegenerative diseases. Its core asset is cutting-edge science and the team that creates it. This chart illustrates its focus on R&D: a small percentage of employees is a sign of a company whose value is determined by the strength of its scientific pipeline.
Number of employees in the market segment - Neuro
Alector is a biotech company specializing in immunoneurology, a novel approach to treating neurodegenerative diseases such as Alzheimer's. This chart shows the cutting edge of science. The growing scientific staff reflects progress in clinical trials of this innovative, yet high-risk, strategy aimed at harnessing the immune system to combat brain diseases.
Number of employees in the market as a whole
Alector is a biotech company focused on immunoneurology for the treatment of degenerative brain diseases. Its staff includes a team of leading scientists in this cutting-edge field. This total employment chart highlights that in the world of high-tech biotech, growth is driven by scientific hypotheses and clinical trial results, not by general economic conditions.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Alector Inc. (ALEC)
Alector is a biotech company specializing in immunoneurology, a new approach to treating neurodegenerative diseases such as Alzheimer's. This chart shows the company's enormous market value per scientist, reflecting investors' belief that the company's revolutionary scientific approach could lead to the first effective treatments.
%20of%20the%20company%20Alector%20Inc.%20(ALEC)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Alector-Inc.-ALEC&v=1772513550394 "Chart of market capitalization per employee (in thousands of dollars) of the company Alector Inc. (ALEC)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Alector is a biopharmaceutical company specializing in immunoneurology for the treatment of degenerative brain diseases. In this highly complex field of medicine, this valuation reflects the high expectations of investors. The high cost per employee indicates that the market sees the revolutionary potential of their scientific approach and highly values the expertise of their team.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772513550462 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Alector is a biopharmaceutical company developing immunotherapy for neurodegenerative diseases. This metric reflects a business at the cutting edge of science. Its market capitalization is based on the potential of its innovative approach. The team's efforts could lead to the creation of a breakthrough treatment, which is valued by the market.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513550593 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Alector Inc. (ALEC)
Alector is a clinical-stage biotech company focused on immuno-neurology (treating brain diseases like Alzheimer's using the immune system). They are not profitable. This chart shows the loss per employee. This is the cost of R&D in one of the most complex and capital-intensive areas of medicine.
%20Chart%20Alector%20Inc.%20(ALEC)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Alector-Inc.-ALEC&v=1772513550620 "Company Profit Per Employee (in thousands of dollars) Chart Alector Inc. (ALEC)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Alector is a biotech company working in the cutting-edge field of immunoneurology (using the immune system to treat brain diseases). The company has no profit, only R&D expenses. This metric reflects R&D capital burn per employee, compared to industry norms for this complex scientific field.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772513550643 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Alector is a biotech company working in the cutting-edge field of immunoneurology (using the immune system to combat brain diseases like Alzheimer's). It has deep R&D. This graph shows the negative value—the high cost of maintaining a team of elite scientists working on one of the most complex problems in medicine.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513550673 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Alector Inc. (ALEC)
Alector is a biopharmaceutical company focused on immunoneurology for the treatment of neurodegenerative diseases. This graph is typical for a clinical-stage company. The lack of revenue per employee means that all of the company's resources and value are concentrated in the potential of its innovative developments.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Alector-Inc.-ALEC&v=1772513550684 "Sales chart per company employee Alector Inc. (ALEC)")
Sales per employee in the market segment - Neuro
Alector (ALEC) is a biotech company specializing in immuno-neurology. They use the immune system to combat neurodegenerative diseases (Alzheimer's, Parkinson's). This chart shows how much revenue (from partnerships) each employee (scientist) generates. It's an indicator of the productivity of their cutting-edge R&D platform.
Sales per employee for the market as a whole
Alector (ALEC) is a biopharmaceutical company specializing in immunoneurology—using the immune system to treat brain diseases (such as Alzheimer's). It has deep R&D. The company has no commercial revenue. This metric does not currently reflect efficacy, but only partner fees (if any).
Short shares by company, segment and market as a whole
Shares shorted by company Alector Inc. (ALEC)
Alector is a biotech company specializing in immunoneurology for the treatment of diseases like Alzheimer's. This chart measures bearish bets. Bears are betting on an extremely high risk of failure in this field, known as the "clinical trials graveyard."
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Alector-Inc.-ALEC&v=1772513550744 "Short Shares Chart for the Company Alector Inc. (ALEC)")
Shares shorted by market segment - Neuro
Alector is a biotech company developing immuno-neurological drugs for the treatment of brain diseases (such as Alzheimer's). This indicator reflects skepticism. "Short" here is a bet on failure in the most complex area of medicine, the "graveyard" of clinical trials—Alzheimer's treatment.
Shares shorted by the overall market
Alector is a biotech company specializing in immunoneurology for the treatment of Alzheimer's and Parkinson's diseases. This is one of the most complex areas of medicine. This chart reflects the overall market pessimism. When investors panic, they often dump biotech stocks working on such complex diseases, where the risk of clinical trial failure is enormous.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Alector Inc. (ALEC)
Alector (ALEC) is a biotech company focused on immuno-neurology. They are developing drugs to treat neurodegenerative diseases (Alzheimer's, Parkinson's) using the immune system. This chart measures hype. It shows "overheated" (above 70) due to positive R&D data (especially from partner GSK) or "oversold" (below 30) due to disappointing results.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Alector-Inc.-ALEC&v=1772513550786 "RSI 14 indicator chart for the company's stock Alector Inc. (ALEC)")
RSI 14 Market Segment - Neuro
Alector (ALEC) — "immune-neurology." This biotech is trying to harness the *immune system* (microglia) to combat *Alzheimer's* and dementia. The RSI_14_Seg for "Neuro" (biotech) shows the overall sentiment. The chart helps us understand: is ALEC's volatility due to the Alzheimer hype, or is the entire sector overheated?
RSI 14 for the overall market
Alector (ALEC) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ALEC (Alector Inc.)
Alector is a biotech company focused on immunoneurology. They develop drugs that harness the brain's immune system to combat neurodegenerative diseases such as Alzheimer's. This chart shows the analysts' average 12-month forecast, representing their collective bet on the success of this cutting-edge science.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ALEC-Alector-Inc.&v=1772513550849 "A chart showing analyst consensus forecasts for the expected stock price. ALEC (Alector Inc.)")
The difference between the consensus estimate and the actual stock price ALEC (Alector Inc.)
Alector is a biotech company at the forefront of immuno-neurology. Their goal is to harness the immune system to treat dementia (Alzheimer's). This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their belief in their scientific breakthrough in the most complex field of medicine.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ALEC-Alector-Inc.&v=1772513550873 "A chart showing the difference between the consensus forecast and the actual stock price. ALEC (Alector Inc.)")
Analyst consensus forecast for stock prices by market segment - Neuro
Alector is a cutting-edge biotech company using the immune system to combat neurodegeneration (Alzheimer's disease). This is high-risk R&D. This chart shows analysts' overall expectations for the entire neuroscience sector. It reflects whether experts believe a breakthrough in Alzheimer's treatment is possible or whether they view the sector as an R&D "graveyard."
Analysts' consensus forecast for the overall market share price
Alector is a biotech company specializing in immunoneurology. They are developing drugs that harness the immune system to combat brain degeneration (Alzheimer's, Parkinson's). This chart shows the overall risk appetite. For Alector, working in the most complex area of medicine, overall market optimism is critical to funding long-term, expensive trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Alector Inc.
Alector is a biotech company at the forefront of treating neurodegenerative diseases (Alzheimer's, dementia). Their approach is immuno-neurology: they attempt to activate the brain's immune system to fight disease. This graph is a clear reflection of their breakthrough science. Its dynamics depend entirely on the results of their clinical trials in this highly complex field.
AKIMA Market Segment Index - Neuro
Alector (ALEC) is a clinical-stage biotech and a pioneer in immuno-neurology. The company is developing breakthrough drugs that utilize the brain's immune system (microglia) to treat Alzheimer's and Parkinson's diseases. This summary metric evaluates R&D. The chart shows the segment average. This benchmark: how does this breakthrough (R&D) focus on Alzheimer's differentiate Alector from the average pharma company?
The AKIM Index for the overall market
Alector is a biotech company, a pioneer in the field of immunoneurology. It develops treatments for Alzheimer's disease by activating the brain's immune system. This chart, reflecting the market average, is an indicator of risk appetite. It reveals the macro backdrop, which is critical for funding such complex scientific bets with binary outcomes.
